BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$90.02 USD
0.00 (0.00%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $90.00 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum B VGM
Zacks News
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
by Zacks Equity Research
Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.
Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%
by Zacks Equity Research
Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.
New Strong Sell Stocks for May 1st
by Zacks Equity Research
AOMR, BMRN and CUTR have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2023.
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 39.53% and 4.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Arcturus Therapeutics (ARCT) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 332.80% and 19.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
by Zacks Equity Research
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.
Should Schwab U.S. Mid-Cap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
by Zacks Equity Research
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
BioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock Down
by Zacks Equity Research
BioMarin (BMRN) reports mixed Q4 results as it misses estimates for earnings but beats the same for sales. Its 2023 sales guidance falls short slightly
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM